Catalyst Pharmaceutical Partners Trading 2.7% Higher After Better-Than-Expected Earnings (CPRX)
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded up 2.7% on Friday following a better than expected earnings announcement, American Banking News.com reports. The stock traded as high as $2.31 and last traded at $2.25, with a volume of 383,955 shares traded. The stock had previously closed at $2.19.
The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02.
The stock has a 50-day moving average of $2.30 and a 200-day moving average of $2.15. The company’s market cap is $150.5 million.
Catalyst Pharmaceutical Partners, Inc is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.
Receive News & Ratings for Catalyst Pharmaceutical Partners Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.